Coagulation factor V as a novel regulator of tumor immunity in melanoma

凝血因子V作为黑色素瘤肿瘤免疫的新型调节因子

阅读:1

Abstract

BACKGROUND: Recent advances in melanoma treatment, including targeted therapies and immunotherapies, have improved patient outcomes. The discovery of molecular targets is crucial, enabling more precise treatment strategies that address specific genetic mutations. Our study delves into the multifunctional role of coagulation factor Coagulation Factor V (F5) in melanoma. METHODS: The melanoma data about gene expression, clinical information, prognosis, and immune infiltration were obtained from TCGA database. The A2058 cell were used to examine the effects of F5 in the behavior of tumor cells in vitro. RESULTS: Our results revealed that F5 expression levels in melanoma patients are significantly correlated with prognosis, with lower expression levels associated with poorer outcomes. Single-cell transcriptomic analysis further revealed a strong association between F5 expression and diverse immune cell populations and chemokines. In addition, overexpression of F5 in the melanoma cell line A2058 significantly inhibited cell migration, proliferation, and colony formation capacity, while upregulating the expression of multiple immune chemokines. CONCLUSIONS: These findings go beyond the traditional view of F5 as a coagulation factor and reveal its importance in immunomodulation and tumor biology.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。